Thread by @TheWonkologist

1/ Time for a quick lit review on whether docs getting money from drug companies influences their prescribing behavior!
#healthpolicy #COI

2/ Among similar TNF-alpha blockers, physicians who got paid by one company were more likely to use that company's drug over others.
ncbi.nlm.nih.gov/pubmed/30324292 @AdeAdamson

3/ Among similar proton-pump inhibitors, physicians who got paid by one company were more likely to use that company's drug over others.
ncbi.nlm.nih.gov/pubmed/30325706

4/ Physicians paid by the manufacturers of degarelix and denosumab, two drugs often used for prostate cancer patients, were somewhat more likely to use those drugs.
ncbi.nlm.nih.gov/pubmed/28149927 @daviesbj

5/ Among similar drugs to treat overactive bladder, physicians who got paid by one company were more likely to use that company's drug over others.
ncbi.nlm.nih.gov/pubmed/29680480 @marthpodi

6/ Among similar intranasal steroids, physicians who got paid by one company were more likely to use that company's drug over others.
ncbi.nlm.nih.gov/pubmed/29865931

7/ ...and, among similar kidney cancer and chronic myeloid leukemia drugs, physicians who got paid by one company were more likely to use that company's drug over others.
ncbi.nlm.nih.gov/pubmed/29630687 (this is my work with @DusetzinaS and @AaronWinn2)

8/ Yes, these results are subject to publication bias. It is possible that other groups have looked at other sets of drugs, found no association, and not moved forward / not been able to publish.

9/ Of published studies, the one that I am aware of that goes against this trend is a study of prostate cancer drugs by @daviesbj &co, which found no association with payments:
ncbi.nlm.nih.gov/pubmed/28749536

10/ For many, the assertion that physician practice may be influenced by such payments seems like common sense. For others this is quite counterintuitive. Always important to follow the data, wherever it leads...